|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Division of Hematology, Department of
Medicine, and Division of Hematopathology, Department of Pathology,
Keck School of Medicine, University of Southern California, Los
Angeles, California; and the HIV Epidemiology Program, Los Angeles
County Department of Health Services, Los Angeles, California.
Over time, the epidemiologic and demographic characteristics
of AIDS have changed in the United States, while the use of highly active antiretroviral therapy has changed the natural history of the
disease. The goal of the study was to ascertain any changes in the
epidemiologic, immunologic, pathologic, or clinical characteristics of
AIDS-related lymphoma (ARL) over the course of the AIDS epidemic. Records of 369 patients with ARL diagnosed or treated at a single institution from 1982 through 1998 were reviewed. Single institutional data were compared to population-based data from the County of Los
Angeles. Significant changes in the demographic profile of patients
with newly diagnosed ARL have occurred, with the later time intervals
associated with a higher prevalence in women (P = .25),
in Latino/Hispanic individuals (P < .0001), and in those who acquired human immunodeficiency virus (HIV) heterosexually (P = .01). These changes were similar in both countywide,
population-based analyses and in those from the single institution. The
median CD4+ lymphocyte count at lymphoma diagnosis has
decreased significantly over the years, from 177/dL in the earliest
time period (1982-1986), to 53/dL in the last time period from 1995 to
1998 (P = .0006). The pathologic spectrum of disease has
also changed, with a decrease in the prevalence of small noncleaved
lymphoma (P = .0005) and an increase in diffuse large
cell lymphoma (P < .0001). Despite changes in the use of
antiretroviral or chemotherapy regimens, the median survival has not
significantly changed.
(Blood. 2000;96:4084-4090) Lymphoma primary to the central nervous system
(CNS) was considered a manifestation of AIDS from the onset of the AIDS
epidemic,1 and systemic high- or intermediate-grade
lymphomas became AIDS defining in 1985.2 AIDS-related
lymphoma (ARL) is usually a late manifestation of infection by the
human immunodeficiency virus (HIV), with a predilection for widespread,
extra nodal disease, involvement of the CNS, and poor
prognosis.3-8
Over time, the epidemiologic and demographic characteristics of AIDS
have changed in the United States. The prevalence of AIDS has increased
among minority populations, in women, and in those who acquired HIV by
heterosexual means.9-11 The widespread use of highly
active antiretroviral therapy (HAART) has also changed the natural
history of the disease,12-14 with a 73% decrease in AIDS-defining opportunistic infections and a 49% decrease in mortality between 1994 and 1996.15 Although HAART has been
associated with a dramatic decrease in the incidence of opportunistic
infections15,16 and Kaposi sarcoma,16-18 the
effect of HAART on ARL is still unclear, although early data suggest no
significant decline.16,19,20 Because of the changing
characteristics of AIDS in general, we wished to ascertain if there
were any changes in the epidemiologic, immunologic, pathologic, or
clinical aspects of ARLs over the course of the AIDS epidemic, from
1982 to 1998.
This is a retrospective study of 369 patients diagnosed and/or
treated at Los Angeles County-University of Southern California (LAC-USC) Medical Center and the USC/Norris Cancer Hospital and Research Institute between 1982 and 1998. All patients were HIV seropositive by enzyme-linked immunosorbent assay with confirmation by
Western blot. All patients had biopsy or cytologically proven non-Hodgkin lymphoma (NHL) and were staged prior to treatment, using
the Ann Arbor staging system.21
A complete history, physical examination, and routine blood work, as
well as T-cell subtypes in the peripheral blood were performed at the
time of diagnosis. Routine staging was performed in all patients when
possible, which included chest radiographs; computed axial tomography
(CAT) scans of the chest, abdomen, and pelvis; lumbar puncture with
cerebrospinal fluid (CSF) analysis; and bone marrow biopsies and
aspirates. A total of 358 (97%) of 369 patients underwent bone marrow
aspirate and biopsy, which was performed from bilateral sites. Lumbar
puncture with analysis of CSF was performed in 353 (95.6%)
patients. CAT scans were performed in all but 7 (98%) patients.
Hospital records, bone marrow pathology reports, laboratory data,
treatment regimens, and response to therapy were reviewed. All
cases underwent uniform pathologic review by one of us (B.N.).
The specific regimens used to treat the 323 patients with systemic
lymphoma and the 46 patients with primary CNS lymphoma are provided in
Figure 1.22-30 In total, 215 patients (67% of treated patients) were enrolled in a prospective
therapeutic protocol.
Demographic data from patients managed at our institution were compared
with the population-based data in the AIDS case registry maintained by
the HIV Epidemiology Program in the Department of Health Services for
the entire County of Los Angeles31 to evaluate the
possibility of referral bias. The Los Angeles County data include all
ARL cases diagnosed from 1982 through 1998 in adults (n = 754). ARL
cases with a missing date of diagnosis or those occurring in children
were excluded.
Statistical analysis
Fisher exact test33 was used to compare differences in
discrete data, and Kruskal-Wallis analysis of variance was used for continuous data.34 Survival curves were constructed as
described by Kaplan and Meier.35
Patient characteristics
Risk factors for HIV infection included male-to-male
sexual transmission in 278 (75%) patients, and heterosexual
transmission in 38 (10%). Relatively few patients reported a history
of injection drug use as the only risk factor for HIV. Over time,
greater numbers of patients with ARL reported heterosexual contact as
their route of initial HIV transmission (P = .011), a
trend confirmed in the population-based data from Los Angeles County
(Figure 3).
HIV-related characteristics
Characteristics of lymphoma at diagnosis Specific characteristics of the lymphomas are provided in Table 2. Systemic lymphoma was diagnosed in 323 (88%) patients, and 46 (12%) had primary CNS lymphoma. No change in the prevalence of primary CNS lymphoma was apparent over time.
The vast majority (97%) of patients were diagnosed with B-cell lymphomas, although minor increases in T-cell lymphomas have recently occurred. Although the most common pathologic subtype of disease (ie, high-grade, small noncleaved lymphoma, diagnosed in 36% overall) has decreased over time from 55% in 1982 through 1986 to 22% of all cases in 1995 through 1998 (P = .0005), the pathologic subtype of diffuse large cell lymphoma has increased significantly over time from 0% in the earlier period to 32% of all cases in the latter time period (P < .0001). As shown in Table 2, although the pathologic spectrum of systemic ARL has changed over time with a significant decline in small noncleaved lymphoma (P = .03) and a significant increase in diffuse large cell lymphoma (P < .0001), the same is not true for patients with primary CNS lymphoma, in which the pathologic diagnoses have not varied significantly over the years of study. In patients with systemic ARL, presence of extranodal lymphomatous disease was commonly found in all time intervals, documented in 56% to 70% of newly diagnosed patients. Further, the specific sites of extranodal disease have not changed appreciably over time. Lymphoma in the bone marrow was seen in 59 (16%) of the whole group, whereas involvement of the CSF occurred in 33 (9%). Liver involvement was found in 67 (19%), and involvement of the rectum occurred in 27 (8%) patients overall. Other sites of extranodal lymphomatous disease are provided (Table 2). Survival Despite changes in median CD4 cell count at ARL diagnosis, in patterns of antiretroviral use, and in various chemotherapeutic regimens, the median survival has remained stable, at approximately 6 months for patients with systemic lymphoma (Figure 4A) and 2 months for those with primary CNS lymphoma (Figure 4B). Nonetheless, patients with systemic lymphoma treated in the latter time interval (1995-1998) may be doing somewhat better, with a median survival of 8.2 months versus 7.4 months in 1982 through 1986, 5.7 months in those treated from 1987 through 1990, and 7.2 months for those treated between 1991 and 1994 (P = .11). No such trend is apparent in patients with primary CNS lymphoma, whose median survival was 2.0 months in the earliest time period and 1.7 months in the latest (P = .66).
In patients with systemic lymphoma, there was no statistical difference in median survival based on stage of disease. Thus, the median survival for stage I patients was 7.8 months versus 13.8 months for those with stage II, 7.7 months for stage III, and 6.5 months for stage IV (P = .23). Further, there were no differences in overall survival during the various time periods when stratifying by stage. Last, there was no difference in the stage of lymphomatous disease at any particular time period. Population-based demographic data of ARL reported in the County of Los Angeles Comparison of demographic data from ARL patients diagnosed and treated at USC and its hospitals and for the County of Los Angeles as a whole is presented in Figures 2 and 3. As shown, trends noted at USC were similar to those in the population-based AIDS registry. When comparing cases reported in 1982 through 1986 to those in the latter time period (1995-1998), a strong trend favoring an increase of ARL in women was seen in the county as a whole (P = .075), with significant increases in Hispanics (P = .007) and a significant decrease in Caucasians (P = .002). There was no significant change in ARL cases reported in African Americans, either in the county of Los Angeles (P = .68) or at the USC Hospitals.
The widespread use of HAART has been associated with a marked reduction in the development of opportunistic infections and a remarkable improvement in overall survival among patients with AIDS.15,16 Similarly, the incidence of Kaposi sarcoma has fallen dramatically in the United States.16-20 The effect of HAART on the incidence of ARL is less clear. Although the majority of studies have failed to demonstrate a major decline in the incidence of systemic ARL,16,17,19,20 other studies18,36 have shown a decrease in the incidence of lymphoma primary to the CNS. Nonetheless, in contrast to Kaposi sarcoma,16 a major decline in the incidence of ARL has not been observed. Although the incidence of ARL has not changed substantially, the current study indicates that the demographic characteristics of disease have evolved toward a greater prevalence of the disease among women and minority populations and among those who acquired HIV by heterosexual contact. The current study represents data from a single institution and would, therefore, potentially be biased by the specific referral patterns in this center. Nonetheless, the LAC-USC Medical Center is a government-operated facility, is the largest hospital in the United States, and serves a largely indigent patient population, who are not specifically referred to our center. The inclusion of patients from the USC/Norris Cancer Hospital (n = 61), a private facility with a large referral base, serves to broaden the scope of patients comprising this report. Furthermore, population-based data from the County of Los Angeles indicate that the changing demographic profile of ARL in the county is quite similar to what we have reported in our own institution. Of interest, the changing demographic profile of patients with AIDS in the United States is also consistent with what we have reported in patients with ARL.11 Thus, the proportion of women among all AIDS cases in the United States has increased from 7% in 1982 to 14% in 1992 and to 23% in 1998. The proportion of Hispanics with AIDS has increased from 13% of all AIDS cases in 1982 to 20% of all AIDS cases in the United States in 1998. Further, the proportion of AIDS among those who acquired HIV by heterosexual means has increased in males from 3.5% in 1992 to 7% in 1997 and in females from 41.3% to 52.6% over the same time interval.1,2,9-11 These data, taken together, would suggest that the demographic changes occurring in patients with ARL are not distinct to the lymphoma, but rather represent part of the larger changes occurring in the AIDS epidemic itself. With the use of the large database from our center, we have also seen a change in the immunologic profile of patients presenting with ARL. In the early years of the epidemic, the median CD4 cell count of our patients at the time of ARL diagnosis was significantly higher than that seen in the more recent time intervals, falling from 177/dL to 53/dL. Lymphoma has been considered a late manifestation of HIV disease,37-40 the incidence of which did not increase substantially until approximately 4 years after the first cases of AIDS had been described.1,2,41 The significant fall in median CD4 cell count in patients with newly diagnosed ARL is consistent with the profound degree of immune suppression that is expected in this disease.4-8,42 Of interest, a fall in median CD4 cell count over recent years may also be seen in reports of several large, prospective national trials conducted through the AIDS Clinical Trials Group (ACTG).26,27 Thus, patients with newly diagnosed AIDS lymphoma accrued to a Phase II study of low-dose methotrexate alternating with standard agents (m-BACOD) between June 1987 and November 1988 had a median CD4 cell count of 150 dL (range 16-1079).26 A subsequent ACTG study, which compared low-dose with standard-dose m-BACOD, accrued patients between February 1991 and October 1994 and had similar eligibility requirements but reported a median study entry CD4 cell count of 100 dL for the low-dose arm and 107 dL for the full-dose arm.27 A substantial increase in CD4 cell count is expected with effective HAART therapy.12,32 The lower CD4 cell count in these recent patients with newly diagnosed ARL may indicate that HAART was ineffective, that HAART was not employed, or that HAART therapy has simply delayed the onset of opportunistic infections or other illnesses, allowing these patients to live long enough to actually develop ARL. The current study has also demonstrated a change in the pathologic spectrum of lymphomatous disease over the years. Although lymphoma pathology may be complex, with substantial interobserver discrepancy,43 all cases in this study have been reviewed and diagnosed by a single, expert hematopathologist (B.N.N.). It is thus unlikely that changes in pathologic diagnosis over time could have occurred because of differing opinions or criteria for diagnosis of these disorders. In patients with systemic ARL, the prevalence of small noncleaved lymphoma has decreased significantly over the time periods, whereas the prevalence of diffuse large cell lymphoma has increased. Similar trends were observed in patients with primary CNS disease. Of interest, small noncleaved NHL has been associated with higher CD4 cell count and earlier onset of lymphoma,40 whereas diffuse large cell or immunoblastic lymphomas have been associated with more profound immune deficiency and lower CD4 cell count.40,44 The current data are consistent with these concepts and support the hypothesis that different pathogenetic mechanisms may be involved in the various pathologic subtypes of ARL.45 In contrast to expectations in HIV-negative intermediate and high-grade lymphoma,46 increasing stage of disease was not associated with poorer prognosis in our patients with ARL. Furthermore, despite changes in specific chemotherapeutic regimens employed over the years, we found no statistically significant difference in median survival times, either for patients with systemic or primary CNS disease. Although the current study does not represent a prospective therapeutic trial, approximately 67% of all treated patients in this series were enrolled in such trials. Of importance, these prospective therapeutic studies have shown no major differences in complete remission rates or overall survival in patients treated with low-dose or standard-dose chemotherapy.26,27,47 Further, although no prospective study has yet compared the use of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) (the 2 regimens used most commonly in our series), outcome data in patients with systemic ARL appear similar with the 2 regimens.27,47,48 The statistically similar median survival times of our patients over the years would be consistent with the concept that no major differences in outcome are expected in patients treated with low-dose or standard-dose therapy, or with m-BACOD versus CHOP chemotherapy in these patients. Despite the use of more effective antiretroviral therapies over time, the median CD4 cell count of our patients has decreased, indicating that these patients may simply have lived long enough to eventually develop lymphoma as a long-term complication of HIV infection. Although median survival is not statistically different when one compares earlier to later time intervals, recent trends would suggest a possible improvement in survival of those with systemic ARL treated in the latter time interval (1995-1998), despite the fact that these patients had significantly lower CD4 cell counts at the time that lymphoma was diagnosed. Because there are no prospective therapeutic data to suggest that the chemotherapeutic regimens were associated with differences in outcome,26,27,47,48 these data would imply that use of HAART may have a substantial beneficial effect on the outcome of patients receiving chemotherapy for ARL, as has been suggested in other studies.49 In this regard, preliminary data would suggest that HAART may be used safely in conjunction with combination chemotherapy for ARL.48 Further study of HAART used together with combination chemotherapy will clearly be of importance.
Submitted June 20, 2000; accepted August 29, 2000.
Supported in part by grants NOA-A1-62540, R01-CA50850, RO1-CA-55510, and UO1 CA 70072, National Institute of Allergy and Infectious Diseases and National Cancer Institute, National Institutes of Health, Public Health Service, Department of Health and Human Services.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alexandra M. Levine, USC/Norris Cancer Hospital, 1441 Eastlake Ave, Rm 3468, NOR 3431, Los Angeles, CA 90033; e-mail: hornor{at}hsc.usc.edu.
1.
Centers for Disease Control.
Update on acquired immune deficiency syndrome (AIDS)
2.
Centers for Disease Control.
Revision of the case definition of acquired immunodeficiency syndrome for national reporting 3. Levine AM, Meyer PR, Begandy MK, et al. Development of B-cell lymphoma in homosexual men: clinical and immunologic findings. Ann Intern Med. 1984;100:7-13. 4. Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men. N Engl J Med. 1984;31:565-570.
5.
Levine AM.
Acquired immunodeficiency syndrome-related lymphoma.
Blood.
1992;80:8-20
6.
Kalter SP, Riggs SA, Cabanillas F, et al.
Aggressive non-Hodgkin's lymphoma in immunocompromised homosexual males.
Blood.
1985;66:655-659 7. Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;108:744-753. 8. Kaplan LD, Abrams DI, Feigal E, et al. AIDS associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989;261:719-724[Abstract].
9.
Centers for Disease Control and Prevention.
Update: AIDS among women
10.
Centers for Disease Control and Prevention.
Update: acquired immunodeficiency deficiency syndrome 11. CDC: US HIV and AIDS cases reported through December 1998. HIV/AIDS Surveillance Report. 1998;10:1-43.
12.
Gulick R, Mellors J, Havlir D, et al.
Indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy.
N Engl J Med.
1997;337:734-739
13.
Hammer SM, Katzenstein DA, Hughes MD, et al.
(ACTG 175): a trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200-500 per cubic millimeter.
N Engl J Med.
1996;335:1081-1090 14. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-1969[Abstract].
15.
Palella FJ Jr, Delaney KM, Moorman AC, et al.
Declining morbidity and mortality among patients with advanced human deficiency infection: HIV Outpatient Study Investigators.
N Engl J Med.
1998;338:853-860
16.
Ledergerber B, Telenti A, Effer M.
Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study.
Br Med J.
1999;319:23-24 17. Rabkin CS, Testa MA, Fischl MA, et al. Declining incidence of Kaposi's sarcoma in AIDS clinical trial group (ACTG) trials [abstract S4]. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:A39. 18. Jones JL, Hanson DL, Ward JW. Effects of anti retro viral therapy on recent trends in cancers among HIV-infected persons [abstract S3]. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:A38. 19. Jacobson LP. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individuals [abstract S5]. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:A39. 20. Buchbinder S, P, Holmberg SD, Scheer S, Colfax G, O'Malley P, Vittinghoff E. Combination anti-retroviral therapy and incidence of AIDS-related malignancies [abstract S7]. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:A39.
21.
Carbone PP, Kaplan HS, Musshoff K, et al.
Report of the committee on Hodgkin's disease staging classification.
Cancer Res.
1971;31:1860-1861 22. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1982;38:1484-1493. 23. Scadden DT, Schenkein DP, Bernstein Z, et al. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer. 1998;83:2580-2587[Medline] [Order article via Infotrieve]. 24. Tulpule A, Espina BM, Levine AM, et al. Treatment of AIDS-related NHL with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study [abstract 93]. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:A39. 25. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983;1:91-98[Abstract]. 26. Levine AM, Wernz JC, Kaplan L, et al. Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA. 1991;226:84-88.
27.
Kaplan LD, Straus DJ, Testa MA, et al.
Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection.
N Engl J Med.
1997;336:1641-1648 28. Levine AM, Tulpule A, Espina B, et al. Low dose m-BACOD with zalcitabine in patients with AIDS-related lymphoma. Cancer. 1996;78:517-526[Medline] [Order article via Infotrieve].
29.
Gill PS, Levine AM, Krailo M, et al.
AIDS related malignant lymphoma: results of prospective treatment trials.
J Clin Oncol.
1987;5:1322-1328 30. Levine AM, Gill PS, Cohen J, et al. Suramin antiviral therapy in AIDS. Ann Intern Med. 1986;105:32-37. 31. Advanced HIV Disease (AIDS) Quarterly Surveillance Summary: cases reported as of December 31, 1998. Los Angeles: Los Angeles County Department of Health Services HIV Epidemiology Department; January 15, 1999.
32.
Corey L, Holmes KK.
Therapy for HIV virus infection 33. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in R × C contingency tables. J Am Stat Assoc. 1983;79:427-434. 34. Rosner B. Fundamentals of Biostatistics. 3rd ed. Boston, Mass: PWS-Kent Publishing; 1990. 35. Kalbfliesch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980. 36. Ammasari A, Cingolani A, Pezzotti P, et al. AIDS-related primary CNS lymphoma: changes of epidemiological trends and of diagnostic attitudes in the era of HAART [abstract S3]. J Acquir Immune Def Synd Hum Retrovirol. 1998;17:A38. 37. Peters BS, Beck EJ, Coleman DG, et al. Changing disease patterns in patients with AIDS in a referral center in the United Kingdom: the changing face of AIDS. Br Med J. 1991;302:203-207. 38. Cote TR, Biggar RF, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997;73:645-650[Medline] [Order article via Infotrieve]. 39. Biggar RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Int J Cancer. 1996;68:754-758[Medline] [Order article via Infotrieve]. 40. Beral V, Peterman T, Berkelman RP, Jaffe H. AIDS-associated non-Hodgkin's lymphoma. Lancet. 1991;337:805-809[Medline] [Order article via Infotrieve]. 41. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR. 1987;36(suppl 1S):1S-15S. 42. Levine AM, Sullivan-Halley J, Gill PS, et al. HIV-related lymphoma: prognostic factors predictive of survival. Cancer. 1991;68:2466-2472[Medline] [Order article via Infotrieve]. 43. NCI Non-Hodgkin's Lymphoma Classification Project Writing Committee. Classification of non-Hodgkin's lymphomas: reproducibility of major classification systems. Cancer. 1985;55:91-95[Medline] [Order article via Infotrieve].
44.
Straus DJ, Huang J, Testa MA, et al.
Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Groups protocol 142
45.
Carbone A, Gaidano G, Gloghini A, et al.
Differential expression of bcl-6, CD138/syndecan-1, and EBV-encoded latent membrane protein-1 identifies distinct histogenetic pathways of AIDSrelated non-Hodgkin's lymphomas.
Blood.
1998;91:747-755
46.
The Non-Hodgkin's Lymphoma Prognostic Factors Project.
Development of a predictive model for aggressive lymphoma: the International NHL Prognostic Factors Project.
N Engl J Med.
1993;329:987-994 47. Tirelli U, Spina M, Gabarre J, et al. Treatment of HIV related non-Hodgkin's lymphoma adapted to prognostic factors. Third National AIDS Malignancy Conference Bethesda: MD; 1999 [abstract 91]. J AIDS. 1999;21:A32. 48. Ratner L, Redden D, Hamzeh F, et al. Chemotherapy for HVI associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third National AIDS Malignancy Conference Bethesda: MD; 1999 [abstract 92]. J AIDS. 1999;21:A32. 49. Romeu J, Navarro T, Tural C, et al. Effect of HAART on response to therapy and survival in patients with AIDS-related non-Hodgkin's lymphoma [abstract TuPeB3162]. Program and abstracts of the XIII International AIDS Conference; Durban, South Africa;; July 9-14, 2000.
© 2000 by The American Society of Hematology.
| ||||||||||
 |
|
 |
|
  L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood, October 15, 2007; 110(8): 2846 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Lim and A. M. Levine Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Levine, A. Tulpule, B. Espina, A. Sherrod, W. D. Boswell, R. D. Lieberman, B. N. Nathwani, and L. Welles Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response J. Clin. Oncol., July 1, 2004; 22(13): 2662 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
Top
Abstract
Introduction
) and the University of Southern
California Medical Center (
).
United States.
MMWR.
1982;31:507-508